OncoArendi weźmie udział w następujących konferencjach i wydarzeniach
ESMO Immuno Oncology Congress Geneva – December 7-10
OncoArendi will present a poster on Friday 8th at 12:30 titled: Novel Dual Arginase 1/2 Inhibitor OATD-02 Improves Efficacy of Immune Checkpoint Inhibitors (ESMO Immuno Oncology 2017).
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 26 – 30, 2017
Philadelphia, Pennsylvania, USA
OncoArendi will present a poster on the Development of OATD-02, a novel arginase 1 and 2 inhibitor for cancer immunotherapy. (Poster Session B, Sunday Oct 29, 2017 12:30 PM – 4:00 PM, Hall E)
ERS – 9-13 September 2017 Milan
OncoArendi will present a poster on The Therapeutic Efficacy of OAT-889 (DualAMCase/CHIT1 Inhibitor) in Comparison to Montelukast in HDM-induced Model of Chronic Airway Inflammation in Mice, on Wednesday 13th, 10th at 8:30 AM. (link: Poster OAT-889 ERS 2017)
ESMO – 8-12 September 2017 Madrid
OncoArendi will present a poster on the development of a novel arginase 1 and 2 inhibitor for cancer immunotherapy, on Sunday, 10th at 1PM. (link: OAT-1746 ESMO 2017)
BIO USA – San Diego 19-22 June 2017
The company presentation will take place on Tuesday, 20th of June, at 3:15 PM in Theatre 4.